Neuren Pharmaceuticals (ASX:NEU) - 주가, 뉴스 및 분석

NEU 주식 개요

바이오 제약 회사인 뉴렌 제약은 신경 장애 치료제를 개발하는 회사입니다. 자세한 내용

NEU 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	1/6
과거 실적	5/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 41.5% 에서 거래

지난 1년간 수익이 113.1% 증가했습니다.

분석가들은 주가가 55.3% 상승할 것이라는 데 동의합니다.

위험 분석

수익은 향후 3년간 연평균 4.1% 씩 감소할 것으로 예상됩니다.

Neuren Pharmaceuticals Limited 경쟁사

Vita Life Sciences

ASX:VLS

AU$117.7m

Vitura Health

ASX:VIT

AU$54.7m

ECS Botanics Holdings

ASX:ECS

AU$21.9m

Telix Pharmaceuticals

ASX:TLX

AU$7.7b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Neuren Pharmaceuticals
과거 주가
현재 주가	AU$17.30
52주 최고치	AU$25.95
52주 최저치	AU$12.02
베타	2.17
11개월 변경	32.97%
3개월 변경 사항	11.11%
1년 변경 사항	16.73%
33년 변화	832.61%
5년 변화	597.58%
IPO 이후 변화	133.78%

최근 뉴스 및 업데이트

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

주주 수익률

	NEU	AU Pharmaceuticals	AU 마켓
7D	20.1%	7.0%	-0.02%
1Y	16.7%	62.0%	14.8%

수익률 대 산업: NEU 지난 1년 동안 62 %를 반환한 Australian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: NEU 지난 1년 동안 14.8 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement	7.4%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.5%

안정적인 주가: NEU 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: NEU 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2001	n/a	Jon Pilcher	www.neurenpharma.com

뉴런파마슈티컬스는 신경계 질환 치료제를 개발하는 바이오 제약 회사입니다. 성인 및 2세 이상 소아 환자의 레트증후군 치료제로 등록되어 있는 데이뷰(트로피네타이드)를 개발 및 상용화하고 있으며, 프래자일 엑스 증후군 치료제로 임상 2상을 진행 중입니다. 또한 펠란-맥더미드 치료제로 임상 2상을 완료한 NNZ-2591과 엔젤만, 피트홉킨스, 프라더-윌 증후군 치료제로 임상 2상을 진행 중인 NNZ-2591을 개발하고 있습니다.

Neuren Pharmaceuticals Limited 기본 사항 요약

Neuren Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NEU 기본 통계
시가총액	AU$2.11b
수익(TTM)	AU$117.29m
수익(TTM)	AU$193.34m

18.9x

P/E 비율

11.4x

P/S 비율

NEU 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NEU 손익 계산서(TTM)
수익	AU$193.34m
수익 비용	AU$32.90m
총 이익	AU$160.44m
기타 비용	AU$43.15m
수익	AU$117.29m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.92
총 마진	82.98%
순이익 마진	60.67%
부채/자본 비율	0%

NEU 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NEU 주식 개요

보상

위험 분석

Neuren Pharmaceuticals Limited 경쟁사

ASX:VLS

AU$117.7m

ASX:VIT

AU$54.7m

ASX:ECS

AU$21.9m

ASX:TLX

AU$7.7b

가격 내역 및 성능

최근 뉴스 및 업데이트

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half 2024 earnings: EPS misses analyst expectations

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Price target decreased by 7.5% to AU$26.54

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth